The lymph nodes are a key tissue site for drug resistance and tumour cell survival in CLL, and interestingly, selinexor overcomes high HLA-E expression induced by the lymph node-derived signals IL-4 and CD40L to enhance NK activation against CLL [62]. This evidence concerns the gene HLA-E and B-cell chronic lymphocytic leukemia.